{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:42:49Z","timestamp":1777934569869,"version":"3.51.4"},"reference-count":14,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Cyclin-dependent kinase 4 and 6 inhibitors, ribociclib and palbociclib, are associated with reports of transaminitis and adverse cardiac events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>The patient is a previously healthy 32-year-old female diagnosed with estrogen receptor-positive, progesterone receptor-positive, and human epidermal growth factor 2 negative metastatic breast cancer. From July to September 2021, the patient was initiated on ribociclib followed by palbociclib for metastatic breast cancer. She subsequently experienced two episodes of transaminitis and was diagnosed with cardiomyopathy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Management and outcome<\/jats:title>\n                    <jats:p>The patient experienced transaminitis 2 weeks after the initiation of ribociclib resulting in discontinuation. When rechallenged with palbociclib, the patient experienced transaminitis within 1 week of initiation, which resulted in discontinuation. Approximately 1 month after palbociclib discontinuation, the patient was diagnosed with congestive heart failure with a left ventricular ejection fraction of 24%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>To our knowledge, there are few case studies investigating cyclin-dependent kinase 4 and 6 inhibitor rechallenge following transaminitis. Prior literature suggests that transaminitis with cyclin-dependent kinase 4 and 6 inhibitors is not a class effect, but this case report suggests otherwise. This report presents a rare case of cardiomyopathy and transaminitis following the administration of cyclin-dependent kinase 4 and 6 inhibitors, ribociclib and palbociclib.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552221122057","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T03:58:39Z","timestamp":1661313519000},"page":"962-966","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Elevated transaminases and development of cardiomyopathy in a 32-year-old woman with metastatic breast cancer after treatment with ribociclib followed by palbociclib"],"prefix":"10.1177","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4715-4659","authenticated-orcid":false,"given":"Christina","family":"Watts","sequence":"first","affiliation":[{"name":"Tom Baker Cancer Centre, Alberta Health Services, Calgary, Canada"},{"name":"Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Nadori","sequence":"additional","affiliation":[{"name":"Tom Baker Cancer Centre, Alberta Health Services, Calgary, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,8,24]]},"reference":[{"key":"bibr1-10781552221122057","unstructured":"Kisquli [package insert on the Internet]. Canada: Novartis Pharmaceuticals Canada Inc.; 2021 [cited 13 February 2022]. Available from: https:\/\/pdf.hres.ca\/dpd_pm\/00062361.PDF."},{"key":"bibr2-10781552221122057","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy109"},{"key":"bibr3-10781552221122057","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.e13038"},{"key":"bibr4-10781552221122057","unstructured":"Ibrance [package insert on the Internet]. United States of America: Pfizer Pharmaceuticals LLC, 2020 [cited 13 February 2022]. Available from: https:\/\/www.accessdata.fda.gov\/spl\/data\/926a661a-371d-41e1-b017-a4942d9defde\/926a661a-371d-41e1-b017-a4942d9defde.xml."},{"key":"bibr5-10781552221122057","unstructured":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD) : National Institute of Diabetes and Digestive and Kidney Diseases; 2012\u20132020. Palbociclib; [cited 13 February 2022]. Available from https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK547882\/."},{"key":"bibr6-10781552221122057","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2020.10.007"},{"key":"bibr7-10781552221122057","doi-asserted-by":"publisher","DOI":"10.1007\/s13691-021-00500-3"},{"key":"bibr8-10781552221122057","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.638895"},{"key":"bibr9-10781552221122057","doi-asserted-by":"publisher","DOI":"10.1093\/abbs\/gmaa066"},{"key":"bibr10-10781552221122057","doi-asserted-by":"publisher","DOI":"10.1159\/000519728"},{"key":"bibr11-10781552221122057","doi-asserted-by":"publisher","DOI":"10.1016\/j.jccase.2021.08.012"},{"key":"bibr12-10781552221122057","doi-asserted-by":"publisher","DOI":"10.1177\/21501327211029230"},{"key":"bibr13-10781552221122057","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"bibr14-10781552221122057","unstructured":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012\u20132019. Adverse Drug Reaction Probability Scale (Naranjo) in Drug Induced Liver Injury. [cited 13 February 2022]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548069\/."}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221122057","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552221122057","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221122057","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:27:30Z","timestamp":1777688850000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552221122057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,24]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1177\/10781552221122057"],"URL":"https:\/\/doi.org\/10.1177\/10781552221122057","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,24]]}}}